miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

OKX Ventures backs STBL in strategic partnership with Hamilton Lane and Securitize to launch RWA-backed stablecoin on X Layer

View original at globenewswire.com
OKX Ventures backs STBL in strategic partnership with Hamilton Lane and Securitize to launch RWA-backed stablecoin on X Layer DUBAI, United Arab Emirates and LONDON and CONSHOHOCKEN, Pa…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • RWA markets are entering a new phase, where tokenization must deliver real utility, not just representation. STBL provides a purpose-built architecture for RWA backed stablecoins combined with compliant yield management. Working with Hamilton Lane and OKX Ventures we are seeking to unlock deeper liquidity, yield management and efficient utility across onchain ecosystems.

    80% confidence
  • This structure shows how tokenization unlocks effective utility when it's paired with regulated issuance and programmable settlement. By embedding institutional private credit directly into onchain money flows, we're turning tokenized assets into functional building blocks: assets that can be settled, composed and used across financial applications, not just held.

    80% confidence
  • The collaboration strengthens the foundation for highly capital efficient RWA products across the network. Working with STBL and Hamilton Lane allows us to accelerate that mission and bring users a more mature RWA ecosystem.

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com